5 days ago
NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'
